Better Drugs, New Targets and Lower Toxicity in Lung Cancer Treatment
Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact qual...
Author: patientpower
Added: 04/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 19, 2017 Category: Cancer & Oncology Source Type: podcasts
How to monitor and manage immunotherapy related events in lung cancer
Alex Spira, MD, PhD, FACP of Virginia Cancer Specialists, Fairfax, VA talks about immunotherapies and the new challenges they present for clinicians. Immunotherapy drugs lead to side effects and toxic...
Author: VJOncology
Added: 02/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 14, 2017 Category: Cancer & Oncology Source Type: podcasts
The toxicities associated with immunotherapy in lung cancer patients
Beth Eaby-Sandy MSN, CRNP, OCN, of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA explains the different toxicities seen with immunotherapy compared to chemotherapy. Toxiciti...
Author: VJOncology
Added: 02/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 14, 2017 Category: Cancer & Oncology Source Type: podcasts
LCI Study: Treating Brain Tumors in a Less Toxic Way
Doctors from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical...
Author: LevineCancerInstitute
Added: 02/09/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2017 Category: Cancer & Oncology Source Type: podcasts
Affordability of Medication: Why Communication With Your Provider Is Essential
Financial toxicity is a big concern with cancer care today. At our recent MPN Town Meeting at City of Hope, MPN experts discuss affordability of medication and why you should be communicating with you...
Author: patientpower
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Expanding your mind about novel psychoactives
The use of novel psychoactive substances is increasing, however there is little information about what these are, and how they work.
Dr Derek Tracy, consultant psychiatrist at Oxleas NHS Foundation Trust, and David Wood, consultant physician and toxicologist at Guy's and St Thomas' NHS Foundation Trust join us to explain that doctors already... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 19, 2017 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Expanding your mind about novel psychoactives
The use of novel psychoactive substances is increasing, however there is little information about what these are, and how they work.
Dr Derek Tracy, consultant psychiatrist at Oxleas NHS Foundation Trust, and David Wood, consultant physician and toxicologist at Guy's and St Thomas' NHS Foundation Trust join us to explain that doctors already know how to deal with these, if they think about them in terms of traditional drug use.
Read the two related articles:
http://www.bmj.com/content/356/bmj.i6814
http://www.bmj.com/content/356/bmj.i6848 (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 19, 2017 Category: General Medicine Authors: BMJ Group Source Type: podcasts
"Evolver" -- The Discovery Files
While environmental change is outpacing the rate of evolution for many other species, Atlantic killifish living in four polluted East Coast estuaries turn out to be remarkably resilient. These fish have adapted to levels of highly toxic industrial pollutants that would normally kill them. (Source: The Discovery Files)
Source: The Discovery Files - January 10, 2017 Category: Science Authors: National Science Foundation Source Type: podcasts
Highlights from ASH 2016: adaptive therapy and reducing toxicity
Ral Crdoba, MD, PhD, of University Hospital Fundacin Jimnez Daz, Madrid, Spain, discusses his two main highlights from ASH 2016. The first highlight includes learning more and more about adaptive...
Author: VJHemOnc
Added: 01/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Drugdrug interactions and their potential impact on toxicity levels in patients with b-cell malignancy
Ral Crdoba, MD, PhD, of University Hospital Fundacin Jimnez Daz, Madrid, Spain, discusses results from a drugdrug interaction study (NCT02381080) of ibrutinib with moderate and strong cytochrome...
Author: VJHemOnc
Added: 01/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Highlights from ASH 2016: adaptive therapy and reducing toxicity
Ral Crdoba, MD, PhD, of University Hospital Infanta Sofa, Madrid, Spain, discusses his two main highlights from ASH 2016. The first highlight includes learning more and more about adaptive therapy ...
Author: VJHemOnc
Added: 01/04/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2017 Category: Cancer & Oncology Source Type: podcasts
Drugdrug interactions and their potential impact on toxicity levels in patients with b-cell malignancy
Ral Crdoba, MD, PhD, of University Hospital Infanta Sofa, Madrid, Spain, discusses results from a drugdrug interaction study (NCT02381080) of ibrutinib with moderate and strong cytochrome p3a (CYP...
Author: VJHemOnc
Added: 01/04/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2017 Category: Cancer & Oncology Source Type: podcasts
Long Term Sickle Cell Treatment Path
Yogenthiran Saunthararajah, MD of Cleveland Clinic discusses potential and non-toxic treatments for Sickle Cell Disease at the 58th ASH Annual Meeting in San Diego, CA.
Author: ASHReport
Added: 12/13/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2016 Category: Cancer & Oncology Source Type: podcasts
